Beta-adrenergic blockers, immunotherapy, and skin testing

Allen P. Kaplan(Medical University of South Carolina), John W. Yunginger(Mayo Clinic in Arizona), Philip Lieberman(University of Tennessee Health Science Center), John A. Anderson(Icahn School of Medicine at Mount Sinai), William E. Pierson, Martin D. Valentine, Lawrence M. Lichtenstein(Johns Hopkins University), Michael Kaliner(Institute for Asthma and Allergy), Guy A. Settipane, Richard F. Lockey(University of South Florida), Albert L. Sheffer, Burton Zweiman

Journal of Allergy and Clinical Immunology

July 1, 1989

10.1016/0091-6749(89)90186-3

Cited by 40

Related Papers

The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria

|Allergy|2018|1.5k

The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

|Allergy|2021|1.2k

The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update

|Allergy|2014|1.2k

Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria

|New England Journal of Medicine|2013|1.1k

A Community-based Study of the Epidemiology of Asthma: Incidence Rates, 1964–1983

|American Review of Respiratory Disease|1992|742